More than 90% of CRC patients have constitutive activation of the Wnt/β‐catenin pathway due to adenomatous polyposis coli (APC) or β‐catenin mutations, which disrupts the cytoplasmic β‐catenin destruction complex and leads to the nuclear translocation of β‐catenin. Here, APC is linked to colorectal carcinoma.